vs

Side-by-side financial comparison of HARVARD BIOSCIENCE INC (HBIO) and LIGHTPATH TECHNOLOGIES INC (LPTH). Click either name above to swap in a different company.

HARVARD BIOSCIENCE INC is the larger business by last-quarter revenue ($23.7M vs $16.4M, roughly 1.5× LIGHTPATH TECHNOLOGIES INC). HARVARD BIOSCIENCE INC runs the higher net margin — -12.0% vs -57.5%, a 45.5% gap on every dollar of revenue. On growth, LIGHTPATH TECHNOLOGIES INC posted the faster year-over-year revenue change (120.2% vs -3.3%). LIGHTPATH TECHNOLOGIES INC produced more free cash flow last quarter ($2.0M vs $-545.0K). Over the past eight quarters, LIGHTPATH TECHNOLOGIES INC's revenue compounded faster (45.7% CAGR vs -1.6%).

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

LightPath Technologies Inc designs, manufactures and distributes high-precision optical components and assemblies, including aspheric lenses, infrared optics, and fiber optic products. It serves global clients across industrial automation, aerospace, defense, medical imaging, and telecommunications sectors.

HBIO vs LPTH — Head-to-Head

Bigger by revenue
HBIO
HBIO
1.5× larger
HBIO
$23.7M
$16.4M
LPTH
Growing faster (revenue YoY)
LPTH
LPTH
+123.6% gap
LPTH
120.2%
-3.3%
HBIO
Higher net margin
HBIO
HBIO
45.5% more per $
HBIO
-12.0%
-57.5%
LPTH
More free cash flow
LPTH
LPTH
$2.5M more FCF
LPTH
$2.0M
$-545.0K
HBIO
Faster 2-yr revenue CAGR
LPTH
LPTH
Annualised
LPTH
45.7%
-1.6%
HBIO

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
HBIO
HBIO
LPTH
LPTH
Revenue
$23.7M
$16.4M
Net Profit
$-2.8M
$-9.4M
Gross Margin
59.7%
36.8%
Operating Margin
7.2%
-52.6%
Net Margin
-12.0%
-57.5%
Revenue YoY
-3.3%
120.2%
Net Profit YoY
-15916.7%
-260.1%
EPS (diluted)
$-0.06
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HBIO
HBIO
LPTH
LPTH
Q4 25
$23.7M
$16.4M
Q3 25
$20.6M
$15.1M
Q2 25
$20.4M
$12.2M
Q1 25
$21.8M
$9.2M
Q4 24
$24.6M
$7.4M
Q3 24
$22.0M
$8.4M
Q2 24
$23.1M
$8.6M
Q1 24
$24.5M
$7.7M
Net Profit
HBIO
HBIO
LPTH
LPTH
Q4 25
$-2.8M
$-9.4M
Q3 25
$-1.2M
$-2.9M
Q2 25
$-2.3M
$-7.1M
Q1 25
$-50.3M
$-3.6M
Q4 24
$18.0K
$-2.6M
Q3 24
$-4.8M
$-1.6M
Q2 24
$-2.9M
$-2.4M
Q1 24
$-4.7M
$-2.6M
Gross Margin
HBIO
HBIO
LPTH
LPTH
Q4 25
59.7%
36.8%
Q3 25
58.4%
29.8%
Q2 25
56.4%
22.0%
Q1 25
56.0%
29.1%
Q4 24
57.1%
26.0%
Q3 24
58.1%
33.9%
Q2 24
57.2%
29.2%
Q1 24
60.3%
20.9%
Operating Margin
HBIO
HBIO
LPTH
LPTH
Q4 25
7.2%
-52.6%
Q3 25
1.0%
-16.6%
Q2 25
-4.0%
-38.0%
Q1 25
-228.1%
-36.3%
Q4 24
0.0%
-33.5%
Q3 24
-8.5%
-16.4%
Q2 24
-9.0%
-25.6%
Q1 24
-9.3%
-33.6%
Net Margin
HBIO
HBIO
LPTH
LPTH
Q4 25
-12.0%
-57.5%
Q3 25
-6.0%
-19.2%
Q2 25
-11.2%
-57.8%
Q1 25
-231.2%
-39.1%
Q4 24
0.1%
-35.2%
Q3 24
-21.9%
-19.3%
Q2 24
-12.7%
-27.3%
Q1 24
-19.1%
-33.7%
EPS (diluted)
HBIO
HBIO
LPTH
LPTH
Q4 25
$-0.06
$-0.20
Q3 25
$-0.03
$-0.07
Q2 25
$-0.05
$0.19
Q1 25
$-1.14
$-0.44
Q4 24
$0.01
$-0.07
Q3 24
$-0.11
$-0.04
Q2 24
$-0.07
$-0.15
Q1 24
$-0.11
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HBIO
HBIO
LPTH
LPTH
Cash + ST InvestmentsLiquidity on hand
$8.6M
$73.6M
Total DebtLower is stronger
$35.9M
Stockholders' EquityBook value
$13.7M
$77.9M
Total Assets
$80.1M
$148.6M
Debt / EquityLower = less leverage
2.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HBIO
HBIO
LPTH
LPTH
Q4 25
$8.6M
$73.6M
Q3 25
$6.8M
Q2 25
$7.4M
$4.9M
Q1 25
$5.5M
Q4 24
$4.1M
Q3 24
$4.6M
Q2 24
$4.0M
Q1 24
$4.3M
Total Debt
HBIO
HBIO
LPTH
LPTH
Q4 25
$35.9M
Q3 25
$34.0M
Q2 25
$34.9M
Q1 25
$36.4M
Q4 24
$37.0M
Q3 24
$34.9M
Q2 24
$35.7M
$535.0K
Q1 24
$35.6M
$599.4K
Stockholders' Equity
HBIO
HBIO
LPTH
LPTH
Q4 25
$13.7M
$77.9M
Q3 25
$14.1M
$21.4M
Q2 25
$15.7M
$15.6M
Q1 25
$14.8M
$15.7M
Q4 24
$63.3M
$26.7M
Q3 24
$65.3M
$29.4M
Q2 24
$67.2M
$30.2M
Q1 24
$68.8M
$31.7M
Total Assets
HBIO
HBIO
LPTH
LPTH
Q4 25
$80.1M
$148.6M
Q3 25
$78.0M
$87.3M
Q2 25
$80.1M
$81.5M
Q1 25
$79.8M
$81.4M
Q4 24
$126.6M
$45.8M
Q3 24
$131.2M
$48.4M
Q2 24
$128.9M
$48.1M
Q1 24
$133.2M
$49.7M
Debt / Equity
HBIO
HBIO
LPTH
LPTH
Q4 25
2.61×
Q3 25
2.41×
Q2 25
2.22×
Q1 25
2.45×
Q4 24
0.58×
Q3 24
0.53×
Q2 24
0.53×
0.02×
Q1 24
0.52×
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HBIO
HBIO
LPTH
LPTH
Operating Cash FlowLast quarter
$-96.0K
$2.8M
Free Cash FlowOCF − Capex
$-545.0K
$2.0M
FCF MarginFCF / Revenue
-2.3%
12.0%
Capex IntensityCapex / Revenue
1.9%
5.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.5M
$-6.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HBIO
HBIO
LPTH
LPTH
Q4 25
$-96.0K
$2.8M
Q3 25
$1.1M
$-1.1M
Q2 25
$2.8M
$-2.6M
Q1 25
$3.0M
$-3.2M
Q4 24
$1.7M
$-737.4K
Q3 24
$-842.0K
$-1.7M
Q2 24
$-846.0K
$64.7K
Q1 24
$1.4M
$-394.2K
Free Cash Flow
HBIO
HBIO
LPTH
LPTH
Q4 25
$-545.0K
$2.0M
Q3 25
$877.0K
$-1.2M
Q2 25
$2.7M
$-3.3M
Q1 25
$2.5M
$-3.7M
Q4 24
$1.4M
$-817.8K
Q3 24
$-1.7M
$-1.8M
Q2 24
$-1.7M
$-225.5K
Q1 24
$758.0K
$-802.5K
FCF Margin
HBIO
HBIO
LPTH
LPTH
Q4 25
-2.3%
12.0%
Q3 25
4.3%
-8.1%
Q2 25
13.0%
-27.3%
Q1 25
11.4%
-40.0%
Q4 24
5.8%
-11.0%
Q3 24
-7.8%
-21.2%
Q2 24
-7.2%
-2.6%
Q1 24
3.1%
-10.4%
Capex Intensity
HBIO
HBIO
LPTH
LPTH
Q4 25
1.9%
5.3%
Q3 25
1.0%
0.5%
Q2 25
0.4%
5.6%
Q1 25
2.4%
4.6%
Q4 24
1.2%
1.1%
Q3 24
4.0%
0.9%
Q2 24
3.5%
3.4%
Q1 24
2.6%
5.3%
Cash Conversion
HBIO
HBIO
LPTH
LPTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
95.83×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HBIO
HBIO

Instruments Equipment Software And Accessories$21.6M91%
Service Maintenance And Warranty Contracts$2.1M9%

LPTH
LPTH

Other$7.9M48%
Infrared Components$5.0M31%
Visible Components$3.4M21%

Related Comparisons